{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:11:55Z","timestamp":1787893915372,"version":"build-2784847793"},"reference-count":139,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK126720"],"award-info":[{"award-number":["R01 DK126720"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK129227"],"award-info":[{"award-number":["R01 DK129227"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL148114"],"award-info":[{"award-number":["R01 HL148114"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 HL169191"],"award-info":[{"award-number":["U54 HL169191"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AHA Transformational Project","award":["24TPA1283630"],"award-info":[{"award-number":["24TPA1283630"]}]},{"name":"Department of Physiology startup"},{"name":"MUSC College of Medicine-Program Project"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypertension (HTN) is one of the key global cardiovascular risk factors, which is tightly linked to kidney health and disease development. Podocytes, glomerular epithelial cells that play a pivotal role in maintenance of the renal filtration barrier, are significantly affected by increased glomerular capillary pressure in HTN. Damage or loss of these cells causes proteinuria, which marks the initiation of the HTN-driven renal damage. It goes without saying that effective blood pressure (BP) management should not only mitigate cardiovascular risks but also preserve renal function by protecting podocyte integrity. This review offers a comprehensive examination of current BP management strategies and their implications for podocyte structure and function and emphasizes strategies for the reduction of proteinuria in HTN. We explore primary and secondary antihypertensive agents, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics, as well as newer therapies (sodium-glucose cotransporter-2 blocking and endothelin receptor antagonism), emphasizing their mechanistic roles in safeguarding podocytes and curtailing proteinuria.<\/jats:p>","DOI":"10.1093\/ajh\/hpae120","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T17:12:20Z","timestamp":1725988340000},"page":"85-96","source":"Crossref","is-referenced-by-count":10,"title":["Blood Pressure Management Strategies and Podocyte Health"],"prefix":"10.1093","volume":"38","author":[{"given":"Marharyta","family":"Semenikhina","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical University of South Carolina , Charleston, South Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy O","family":"Mathew","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, VA Loma Linda Healthcare System , Loma Linda, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munsef","family":"Barakat","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical University of South Carolina , Charleston, South Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin P","family":"Van Beusecum","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical University of South Carolina , Charleston, South Carolina,","place":["USA"]},{"name":"Ralph H. Johnson VA Medical Center , Charleston, South Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria V","family":"Ilatovskaya","sequence":"additional","affiliation":[{"name":"Department of Physiology, Medical College of Georgia, Augusta University , Augusta, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-5527","authenticated-orcid":false,"given":"Oleg","family":"Palygin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical University of South Carolina , Charleston, South Carolina,","place":["USA"]},{"name":"Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina , Charleston, South Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"2025092823215735500_CIT0001","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2022.07.005","article-title":"Harmonization of the American College of Cardiology\/American Heart Association and European Society of Cardiology\/European Society of Hypertension Blood Pressure\/Hypertension Guidelines: comparisons, reflections, and recommendations","volume":"80","author":"Whelton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025092823215735500_CIT0002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025092823215735500_CIT0003","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","article-title":"The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens Res"},{"key":"2025092823215735500_CIT0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","article-title":"Hypertension pharmacological treatment in adults: a World Health Organization guideline executive summary","volume":"79","author":"Al-Makki","year":"2022","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0005","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025092823215735500_CIT0006","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(13)60311-6","article-title":"Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease","volume":"382","author":"Luyckx","year":"2013","journal-title":"Lancet"},{"key":"2025092823215735500_CIT0008","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"2025092823215735500_CIT0009","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MNH.0000000000000492","article-title":"Blood pressure targets and kidney and cardiovascular disease: same data but discordant guidelines","volume":"28","author":"Roehm","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025092823215735500_CIT0010","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2215\/CJN.03050509","article-title":"Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular disease","volume":"4","author":"Weir","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0011","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.kint.2016.04.016","article-title":"Hypertension and glomerular function decline: the chicken or the egg","volume":"90","author":"Stengel","year":"2016","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0012","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.kint.2016.03.021","article-title":"Elevated blood pressure is not associated with accelerated glomerular filtration rate decline in the general non-diabetic middle-aged population","volume":"90","author":"Eriksen","year":"2016","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0013","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.117.09208","article-title":"Increased perfusion pressure drives renal t-cell infiltration in the dahl salt-sensitive rat","volume":"70","author":"Evans","year":"2017","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0014","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41467-021-21301-5","article-title":"Renal metabolism and hypertension","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"key":"2025092823215735500_CIT0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41581-018-0018-2","article-title":"The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease","volume":"14","author":"Yang","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2025092823215735500_CIT0016","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41581-019-0121-z","article-title":"Immune mechanisms of salt-sensitive hypertension and renal end-organ damage","volume":"15","author":"Mattson","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025092823215735500_CIT0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2478\/jtim-2020-0033","article-title":"Pathogenesis and damage targets of hypertensive kidney injury","volume":"8","author":"Sun","year":"2020","journal-title":"J Transl Int Med"},{"key":"2025092823215735500_CIT0018","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2215\/CJN.09400913","article-title":"The glomerulus: the sphere of influence","volume":"9","author":"Pollak","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0019","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.akdh.2022.12.003","article-title":"Targeting glomerular hemodynamics for kidney protection","volume":"30","author":"Savedchuk","year":"2023","journal-title":"Adv Kidney Dis Health"},{"key":"2025092823215735500_CIT0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000481633","article-title":"A review of podocyte biology","volume":"47","author":"Garg","year":"2018","journal-title":"Am J Nephrol"},{"key":"2025092823215735500_CIT0021","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1097\/HJH.0000000000001747","article-title":"Urinary podocyte-associated molecules and albuminuria in hypertension","volume":"36","author":"Perez-Hernandez","year":"2018","journal-title":"J Hypertens"},{"key":"2025092823215735500_CIT0022","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/HJH.0b013e328352b89a","article-title":"Development of structural kidney damage in spontaneously hypertensive rats","volume":"30","author":"Hultstrom","year":"2012","journal-title":"J Hypertens"},{"key":"2025092823215735500_CIT0023","doi-asserted-by":"crossref","first-page":"F40","DOI":"10.1152\/ajprenal.00404.2002","article-title":"Urinary excretion of viable podocytes in health and renal disease","volume":"285","author":"Vogelmann","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025092823215735500_CIT0024","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.12998\/wjcc.v7.i22.3698","article-title":"Human podocyte injury in the early course of hypertensive renal injury","volume":"7","author":"Sun","year":"2019","journal-title":"World J Clin Cases"},{"key":"2025092823215735500_CIT0025","doi-asserted-by":"crossref","first-page":"F656","DOI":"10.1152\/ajprenal.00497.2015","article-title":"Human podocyte depletion in association with older age and hypertension","volume":"310","author":"Puelles","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025092823215735500_CIT0026","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1440-1827.1998.tb03920.x","article-title":"Adaptation and distortion of podocytes in rat remnant kidney","volume":"48","author":"Shimojo","year":"1998","journal-title":"Pathol Int"},{"key":"2025092823215735500_CIT0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-016-0735-5","article-title":"Podocytes: the Weakest Link in Diabetic Kidney Disease","volume":"16","author":"Lin","year":"2016","journal-title":"Curr Diab Rep"},{"key":"2025092823215735500_CIT0028","doi-asserted-by":"crossref","first-page":"F333","DOI":"10.1152\/ajprenal.00478.2012","article-title":"The podocyte\u2019s response to stress: the enigma of foot process effacement","volume":"304","author":"Kriz","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025092823215735500_CIT0029","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1681\/ASN.2014030278","article-title":"A potential role for mechanical forces in the detachment of podocytes and the progression of CKD","volume":"26","author":"Kriz","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.ackd.2014.05.009","article-title":"The pathogenesis of focal segmental glomerulosclerosis","volume":"21","author":"Jefferson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025092823215735500_CIT0031","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2024.05.008","article-title":"Cardiovascular and Kidney Outcomes of Non-Diabetic CKD by Albuminuria Severity: findings from the CRIC Study","author":"Shulman","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2025092823215735500_CIT0032","first-page":"1","article-title":"The relationship between low levels of albuminuria and mortality among adults without major cardiovascular risk factors","volume":"00","author":"Claudel","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025092823215735500_CIT0033","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2025092823215735500_CIT0034","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ckj\/sfx136","article-title":"What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis","volume":"11","author":"Gonzalez-Quiroz","year":"2018","journal-title":"Clin Kidney J"},{"key":"2025092823215735500_CIT0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0036","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0037","doi-asserted-by":"crossref","first-page":"21563","DOI":"10.1038\/s41598-022-26162-6","article-title":"Podocyturia: an earlier biomarker of cardiovascular outcomes","volume":"12","author":"Eid","year":"2022","journal-title":"Sci Rep"},{"key":"2025092823215735500_CIT0038","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.kint.2020.03.038","article-title":"Podocyte stress and detachment measured in urine are related to mean arterial pressure in healthy humans","volume":"98","author":"Naik","year":"2020","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0039","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1053\/j.ajkd.2019.12.019","article-title":"Approach to diagnosis and management of primary glomerular diseases due to podocytopathies in adults: core curriculum 2020","volume":"75","author":"Ahn","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025092823215735500_CIT0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet"},{"key":"2025092823215735500_CIT0041","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/ckj\/sfv090","article-title":"A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues","volume":"8","author":"Wada","year":"2015","journal-title":"Clin Kidney J"},{"key":"2025092823215735500_CIT0042","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMc1903250","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Carriazo","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092823215735500_CIT0043","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12882-018-1132-x","article-title":"Minimal change nephrotic syndrome in patients infected with human immunodeficiency virus: a retrospective study of 8 cases","volume":"19","author":"Arrestier","year":"2018","journal-title":"BMC Nephrol"},{"key":"2025092823215735500_CIT0044","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.00860115","article-title":"Drug-induced glomerular disease: direct cellular injury","volume":"10","author":"Markowitz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0045","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N Engl J Med"},{"key":"2025092823215735500_CIT0046","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0272-6386(89)80001-0","article-title":"Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis","volume":"13","author":"Rennke","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"2025092823215735500_CIT0047","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/CIRCRESAHA.120.318711","article-title":"Renin cell baroreceptor, a nuclear mechanotransducer central for homeostasis","volume":"129","author":"Watanabe","year":"2021","journal-title":"Circ Res"},{"key":"2025092823215735500_CIT0048","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1113\/jphysiol.1978.sp012318","article-title":"The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat","volume":"278","author":"Al-Merani","year":"1978","journal-title":"J Physiol"},{"key":"2025092823215735500_CIT0049","first-page":"809","article-title":"Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension","volume":"3","author":"Allikmets","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"2025092823215735500_CIT0050","doi-asserted-by":"crossref","first-page":"e12648","DOI":"10.1111\/jfbc.12648","article-title":"Food protein-derived renin-inhibitory peptides: in vitro and in vivo properties","volume":"43","author":"Aluko","year":"2019","journal-title":"J Food Biochem"},{"key":"2025092823215735500_CIT0051","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/jch.12828","article-title":"Benefits and risks of aliskiren treatment in patients with type 2 diabetes: analyses of the 3A registry","volume":"18","author":"Kistner","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025092823215735500_CIT0052","doi-asserted-by":"crossref","first-page":"89364","DOI":"10.18632\/oncotarget.19382","article-title":"Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"2025092823215735500_CIT0053","doi-asserted-by":"crossref","first-page":"115466","DOI":"10.1016\/j.bmc.2020.115466","article-title":"Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. a fleeting look at the old and the promising new molecules","volume":"28","author":"Ramya","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"2025092823215735500_CIT0054","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3949\/ccjm.86a.19016","article-title":"ACE inhibitor and ARB therapy: practical recommendations","volume":"86","author":"Rincon-Choles","year":"2019","journal-title":"Cleve Clin J Med"},{"key":"2025092823215735500_CIT0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/10641963.2017.1407333","article-title":"Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats","volume":"40","author":"Abdel Kawy","year":"2018","journal-title":"Clin Exp Hypertens"},{"key":"2025092823215735500_CIT0056","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MAJ.0b013e318245fdaa","article-title":"Renin induces apoptosis in podocytes through a receptor-mediated, angiotensin II-independent mechanism","volume":"344","author":"Yuan","year":"2012","journal-title":"Am J Med Sci"},{"key":"2025092823215735500_CIT0057","first-page":"825","article-title":"Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db\/db mice: should the combination therapy be a focus","volume":"7","author":"Zhou","year":"2015","journal-title":"Am J Transl Res"},{"key":"2025092823215735500_CIT0058","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/1470320313507123","article-title":"Protective effects of aliskiren and valsartan in mice with diabetic nephropathy","volume":"15","author":"Wang","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025092823215735500_CIT0059","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1470320312459980","article-title":"Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury","volume":"14","author":"Rashikh","year":"2013","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025092823215735500_CIT0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12872-020-01442-z","article-title":"Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2025092823215735500_CIT0061","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.101.8.844","article-title":"Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure","volume":"101","author":"Jorde","year":"2000","journal-title":"Circulation"},{"key":"2025092823215735500_CIT0062","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis Chronic Kidney Disease stages 3-5: a network meta-analysis of Randomised Clinical Trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"2025092823215735500_CIT0063","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3949\/ccjm.86a.18024","article-title":"ACE inhibitors and ARBs: managing potassium and renal function","volume":"86","author":"Momoniat","year":"2019","journal-title":"Cleve Clin J Med"},{"key":"2025092823215735500_CIT0064","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1470320314543910","article-title":"ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation","volume":"16","author":"Zhang","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025092823215735500_CIT0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2353\/ajpath.2009.080227","article-title":"Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition","volume":"174","author":"Macconi","year":"2009","journal-title":"Am J Pathol"},{"key":"2025092823215735500_CIT0066","doi-asserted-by":"crossref","first-page":"e174558","DOI":"10.1172\/JCI174558","article-title":"Neuronally differentiated macula densa cells regulate tissue remodeling and regeneration in the kidney","volume":"134","author":"Gyarmati","year":"2024","journal-title":"J Clin Invest"},{"key":"2025092823215735500_CIT0067","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1681\/ASN.V113477","article-title":"Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats","volume":"11","author":"Macconi","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0068","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FJC.0000000000000208","article-title":"AT2 receptor activities and pathophysiological implications","volume":"65","author":"Matavelli","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025092823215735500_CIT0069","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/dom.15181","article-title":"Management of the \u2018wicked\u2019 combination of heart failure and chronic kidney disease in the patient with diabetes","volume":"25","author":"Bell","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025092823215735500_CIT0070","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.cardfail.2022.10.432","article-title":"Angiotensin Receptor Neprilysin Inhibitor use and blood pressure lowering in patients with heart failure with reduced ejection fraction across the spectrum of kidney function: an analysis of the Veterans Administrative Health System","volume":"29","author":"Gjyriqi","year":"2023","journal-title":"J Card Fail"},{"key":"2025092823215735500_CIT0071","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of Sacubitril\/Valsartan Versus Irbesartan in patients with Chronic Kidney Disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2025092823215735500_CIT0072","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/biom12060745","article-title":"Nitric-Oxide-mediated signaling in Podocyte Pathophysiology","volume":"12","author":"Semenikhina","year":"2022","journal-title":"Biomolecules"},{"key":"2025092823215735500_CIT0073","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.3390\/ijms23116018","article-title":"Podocyte-related mechanisms underlying survival benefit of long-term angiotensin receptor blocker","volume":"23","author":"Zhu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025092823215735500_CIT0074","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/HYPERTENSIONAHA.109.141994","article-title":"Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent","volume":"55","author":"Matsusaka","year":"2010","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0075","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1152\/ajprenal.00184.2016","article-title":"The podocyte as a direct target for treatment of glomerular disease","volume":"311","author":"Mallipattu","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025092823215735500_CIT0076","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1097\/01.ASN.0000032544.37147.AE","article-title":"Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers","volume":"13","author":"Deferrari","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0077","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1681\/ASN.2005050522","article-title":"Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering","volume":"16","author":"Izuhara","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0078","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/ki.2015.178","article-title":"Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria","volume":"88","author":"Hayashi","year":"2015","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0079","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1523-1755.2004.00362.x","article-title":"Activation of a local tissue angiotensin system in podocytes by mechanical strain","volume":"65","author":"Durvasula","year":"2004","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0080","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2353\/ajpath.2007.060484","article-title":"Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall","volume":"170","author":"Suzuki","year":"2007","journal-title":"Am J Pathol"},{"key":"2025092823215735500_CIT0081","doi-asserted-by":"crossref","first-page":"F532","DOI":"10.1152\/ajprenal.00316.2023","article-title":"RAS-mediated nitric oxide signaling in podocytes","volume":"327","author":"Semenikhina","year":"2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025092823215735500_CIT0082","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41598-017-00406-2","article-title":"The role of Angiotensin II in Glomerular volume dynamics and podocyte calcium handling","volume":"7","author":"Ilatovskaya","year":"2017","journal-title":"Sci Rep"},{"key":"2025092823215735500_CIT0083","doi-asserted-by":"crossref","first-page":"17637","DOI":"10.1038\/srep17637","article-title":"Podocyte injury in diabetic nephropathy: implications of angiotensin II-dependent activation of TRPC channels","volume":"5","author":"Ilatovskaya","year":"2015","journal-title":"Sci Rep"},{"key":"2025092823215735500_CIT0084","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00007611-198902000-00022","article-title":"Rapid and simple metachromatic stain for Pneumocystis carinii","volume":"82","author":"Woosley","year":"1989","journal-title":"South Med J"},{"key":"2025092823215735500_CIT0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"2025092823215735500_CIT0086","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1042\/CS20230313","article-title":"Beta-Arrestin pathway activation by selective ATR1 Agonism promotes calcium influx in podocytes, leading to Glomerular damage","volume":"137","author":"Semenikhina","year":"2023","journal-title":"Clin Sci (London)"},{"key":"2025092823215735500_CIT0087","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1152\/physrev.00013.2022","article-title":"Ion channels and channelopathies in glomeruli","volume":"103","author":"Staruschenko","year":"2023","journal-title":"Physiol Rev"},{"key":"2025092823215735500_CIT0088","article-title":"Calcium Channel Blockers","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"2025092823215735500_CIT0089","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1074248414530508","article-title":"Calcium channel blockers in cardiovascular pharmacotherapy","volume":"19","author":"Godfraind","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025092823215735500_CIT0090","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1007\/s11255-022-03183-8","article-title":"N-type calcium channel and renal injury","volume":"54","author":"Bai","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"2025092823215735500_CIT0091","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.RES.0000256155.31133.49","article-title":"Ca2+ channel subtypes and pharmacology in the kidney","volume":"100","author":"Hayashi","year":"2007","journal-title":"Circ Res"},{"key":"2025092823215735500_CIT0092","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/hr.2015.69","article-title":"Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis","volume":"38","author":"Thamcharoen","year":"2015","journal-title":"Hypertens Res"},{"key":"2025092823215735500_CIT0093","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1751-7176.2008.00016.x","article-title":"Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy","volume":"10","author":"Toto","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025092823215735500_CIT0094","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000072054","article-title":"Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension","volume":"23","author":"Hayashi","year":"2003","journal-title":"Am J Nephrol"},{"key":"2025092823215735500_CIT0095","doi-asserted-by":"crossref","first-page":"27192","DOI":"10.1038\/srep27192","article-title":"Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure","volume":"6","author":"Ohno","year":"2016","journal-title":"Sci Rep"},{"key":"2025092823215735500_CIT0096","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/ph16030338","article-title":"N-\/T-Type vs. L-Type calcium channel blocker in treating chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025092823215735500_CIT0097","doi-asserted-by":"crossref","first-page":"6653851","DOI":"10.1155\/2020\/6653851","article-title":"Effects of L-\/N-Type calcium channel blockers on angiotensin II-renin feedback in hypertensive patients","volume":"2020","author":"Kawabata","year":"2020","journal-title":"Int J Hypertens"},{"key":"2025092823215735500_CIT0098","doi-asserted-by":"crossref","first-page":"173513","DOI":"10.1016\/j.ejphar.2020.173513","article-title":"L-type calcium channel blockers decrease the iron overload-mediated oxidative stress in renal epithelial cells by reducing iron accumulation","volume":"886","author":"Sun","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025092823215735500_CIT0099","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.hfc.2022.03.005","article-title":"Renoprotective effects of SGLT2 inhibitors","volume":"18","author":"Vallon","year":"2022","journal-title":"Heart Fail Clin"},{"key":"2025092823215735500_CIT0100","doi-asserted-by":"crossref","first-page":"F692","DOI":"10.1152\/ajprenal.00053.2022","article-title":"SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na(+) transport in Dahl SS rats","volume":"322","author":"Kravtsova","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025092823215735500_CIT0101","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"2025092823215735500_CIT0102","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/j.2040-4603.2011.tb00365.x","article-title":"Pathophysiology of the diabetic kidney","volume":"1","author":"Vallon","year":"2011","journal-title":"Compr Physiol"},{"key":"2025092823215735500_CIT0103","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/s41467-022-31772-9","article-title":"Single-cell analysis highlights differences in druggable pathways underlying adaptive or fibrotic kidney regeneration","volume":"13","author":"Balzer","year":"2022","journal-title":"Nat Commun"},{"key":"2025092823215735500_CIT0104","doi-asserted-by":"crossref","first-page":"e98720","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"2025092823215735500_CIT0105","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy","volume":"9","author":"Bessho","year":"2019","journal-title":"Sci Rep"},{"key":"2025092823215735500_CIT0106","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.medj.2022.10.001","article-title":"One size fits all: the story of SGLT2 inhibitors in heart failure","volume":"3","author":"Verma","year":"2022","journal-title":"Med"},{"key":"2025092823215735500_CIT0107","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025092823215735500_CIT0108","doi-asserted-by":"crossref","first-page":"e3922","DOI":"10.1002\/cbf.3922","article-title":"SGLT2 inhibitors and AMPK: the road to cellular housekeeping","volume":"42","author":"Safaie","year":"2024","journal-title":"Cell Biochem Funct"},{"key":"2025092823215735500_CIT0109","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/biomedicines9050576","article-title":"Systemic actions of SGLT2 Inhibition on Chronic mTOR activation as a shared pathogenic mechanism between Alzheimer\u2019s Disease and Diabetes","volume":"9","author":"Stanciu","year":"2021","journal-title":"Biomedicines"},{"key":"2025092823215735500_CIT0110","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/dom.14503","article-title":"Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation","volume":"23","author":"Kim","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025092823215735500_CIT0111","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.3390\/cells11233913","article-title":"Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the effect of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"11","author":"Chen","year":"2022","journal-title":"Cells"},{"key":"2025092823215735500_CIT0112","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/S0140-6736(22)02181-X","article-title":"Endothelin antagonists and the quest for a new therapeutic option in resistant hypertension","volume":"400","author":"Dechend","year":"2022","journal-title":"Lancet"},{"key":"2025092823215735500_CIT0113","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cca.2020.03.008","article-title":"The endothelin system as target for therapeutic interventions in cardiovascular and renal disease","volume":"506","author":"Eroglu","year":"2020","journal-title":"Clin Chim Acta"},{"key":"2025092823215735500_CIT0114","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2025092823215735500_CIT0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MNH.0b013e328335f91f","article-title":"Endothelin, hypertension and chronic kidney disease: new insights","volume":"19","author":"Kohan","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025092823215735500_CIT0116","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000504623","article-title":"The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease","volume":"6","author":"Raina","year":"2020","journal-title":"Kidney Dis (Basel)"},{"key":"2025092823215735500_CIT0117","first-page":"e19325","article-title":"Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: a systematic review","volume":"13","author":"Ahmad","year":"2021","journal-title":"Cureus"},{"key":"2025092823215735500_CIT0118","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000094397.19932.78","article-title":"Endothelin receptor blockers in cardiovascular disease","volume":"108","author":"Rich","year":"2003","journal-title":"Circulation"},{"key":"2025092823215735500_CIT0119","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2362.2009.02119.x","article-title":"Endothelin receptor selectivity in chronic renal failure","volume":"39","author":"Longaretti","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"2025092823215735500_CIT0120","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41467-023-36998-9","article-title":"Structural basis of peptide recognition and activation of endothelin receptors","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"2025092823215735500_CIT0121","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/j.2040-4603.2011.tb00344.x","article-title":"Physiology of endothelin and the kidney","volume":"1","author":"Kohan","year":"2011","journal-title":"Compr Physiol"},{"key":"2025092823215735500_CIT0122","doi-asserted-by":"crossref","first-page":"659013","DOI":"10.3389\/fmed.2021.659013","article-title":"Glomerular Endothelial cell crosstalk with Podocytes in Diabetic Kidney Disease","volume":"8","author":"Mahtal","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025092823215735500_CIT0123","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1681\/ASN.2013020195","article-title":"Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis","volume":"25","author":"Lenoir","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025092823215735500_CIT0124","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.kint.2019.05.007","article-title":"Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells","volume":"96","author":"Ebefors","year":"2019","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0125","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.110.156570","article-title":"Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat","volume":"56","author":"Saleh","year":"2010","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0126","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/01.HYP.35.6.1237","article-title":"Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo","volume":"35","author":"Cardillo","year":"2000","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0127","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3390\/cells10040869","article-title":"Abnormal crosstalk between Endothelial cells and podocytes mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity","volume":"10","author":"Gu","year":"2021","journal-title":"Cells"},{"key":"2025092823215735500_CIT0128","doi-asserted-by":"crossref","first-page":"212531","DOI":"10.7573\/dic.212531","article-title":"Combination therapy in the treatment of hypertension","volume":"7","author":"Guerrero-Garcia","year":"2018","journal-title":"Drugs Context"},{"key":"2025092823215735500_CIT0129","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","article-title":"Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis","volume":"65","author":"Olde Engberink","year":"2015","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0130","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced Chronic Kidney Disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"2025092823215735500_CIT0131","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000517020","article-title":"The forgotten Antiproteinuric properties of Diuretics","volume":"52","author":"Trujillo","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025092823215735500_CIT0132","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2025092823215735500_CIT0133","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"2025092823215735500_CIT0134","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ejhf.2740","article-title":"The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure","volume":"25","author":"Lin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025092823215735500_CIT0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"2025092823215735500_CIT0136","doi-asserted-by":"crossref","first-page":"46624","DOI":"10.1038\/srep46624","article-title":"Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition","volume":"7","author":"Kato","year":"2017","journal-title":"Sci Rep"},{"key":"2025092823215735500_CIT0137","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/ndt\/gfq750","article-title":"Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production","volume":"26","author":"Toyonaga","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2025092823215735500_CIT0138","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000534808","article-title":"Study design and baseline characteristics for aldosterone synthase inhibition in CKD","volume":"55","author":"Tuttle","year":"2023","journal-title":"Am J Nephrol"},{"key":"2025092823215735500_CIT0139","doi-asserted-by":"crossref","first-page":"F1009","DOI":"10.1152\/ajprenal.00206.2017","article-title":"Sex and gender differences in hypertensive kidney injury","volume":"313","author":"Sullivan","year":"2017","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpae120\/59739564\/hpae120.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/2\/85\/59739564\/hpae120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/2\/85\/59739564\/hpae120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T03:22:26Z","timestamp":1759116146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/38\/2\/85\/7756359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":139,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,12]]},"published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpae120","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,12]]}}}